AEON Biopharma (AEON) Projected to Release Quarterly Earnings on Tuesday

AEON Biopharma (NASDAQ:AEON) will likely be releasing its results before the market opens on Tuesday, August 11th. Analysts expect AEON Biopharma to post earnings of ($0.2250) per share for the quarter.

AEON Biopharma Price Performance

Shares of NASDAQ AEON traded up $0.01 during mid-day trading on Tuesday, hitting $0.31. The company had a trading volume of 221,292 shares, compared to its average volume of 628,976. AEON Biopharma has a 12 month low of $0.22 and a 12 month high of $1.45. The firm has a market cap of $7.74 million, a P/E ratio of 1.71 and a beta of 0.61. The business’s 50-day simple moving average is $0.57 and its 200-day simple moving average is $0.87.

Hedge Funds Weigh In On AEON Biopharma

A hedge fund recently raised its stake in AEON Biopharma stock. Geode Capital Management LLC increased its stake in shares of AEON Biopharma, Inc. (NASDAQ:AEON) by 27.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,134 shares of the company’s stock after buying an additional 13,061 shares during the period. Geode Capital Management LLC owned 0.51% of AEON Biopharma worth $66,000 at the end of the most recent quarter. 22.78% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AEON. Lake Street Capital began coverage on AEON Biopharma in a research report on Thursday, July 30th. They set a “buy” rating and a $1.00 price objective on the stock. Zacks Research raised shares of AEON Biopharma to a “hold” rating in a report on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, AEON Biopharma presently has a consensus rating of “Buy” and a consensus price target of $1.00.

About AEON Biopharma

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.